<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biological response modifier for the treatment of bladder cancer"</p><p>BMC Cancer 2004;4():86-86.</p><p>Published online 26 Nov 2004</p><p>PMCID:PMC544192.</p><p>Copyright © 2004 Sänger et al; licensee BioMed Central Ltd.</p>(A/B) or L-particle loaded with PstS1 (C). On days 1, 8, 15 and 22 after tumor challenge, mice were treated by intravesical instillation of PstS1 (A/C) or PBS (B). Mice which received s.c. PBS and intravesical PBS served as control. Survival of mice was analyzed by Kaplan-Meier curve and log rank test
Background The therapeutic armamentarium of bladder cancer has been recently enriched with the intro...
<div><p>Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent ...
Approximately 80% of patients with advanced bladder cancer do not respond to immune checkpoint inhib...
<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biolo...
<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biolo...
<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biolo...
<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biolo...
Purpose: Bacillus Calmette-Guerin (BCG) continues to be employed as the most effective immunotherapy...
Abstract Background Bacillus Calmette Guérin (BCG)-immunotherapy has a well-documented and successfu...
Since intravesical Bacillus Calmette-Guerin (BCG) began to be used for bladder cancer, our understan...
Background: For more than 20 years, superficial bladder tumors have been demonstrated to be sensitiv...
C57BL/6 (WT) and PLT2 mice were challenged with B16 tumor cells and given peri-tumoral injections of...
<p>Six mice/group were immunized three times with P<sub>5+435</sub> long peptide alone, long peptide...
<p><b>Copyright information:</b></p><p>Taken from "Repeated BCG treatment of mouse bladder selective...
Rationale: Organ- or tissue-specific antigens produced by normal tissue or by cancer cells could be ...
Background The therapeutic armamentarium of bladder cancer has been recently enriched with the intro...
<div><p>Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent ...
Approximately 80% of patients with advanced bladder cancer do not respond to immune checkpoint inhib...
<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biolo...
<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biolo...
<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biolo...
<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biolo...
Purpose: Bacillus Calmette-Guerin (BCG) continues to be employed as the most effective immunotherapy...
Abstract Background Bacillus Calmette Guérin (BCG)-immunotherapy has a well-documented and successfu...
Since intravesical Bacillus Calmette-Guerin (BCG) began to be used for bladder cancer, our understan...
Background: For more than 20 years, superficial bladder tumors have been demonstrated to be sensitiv...
C57BL/6 (WT) and PLT2 mice were challenged with B16 tumor cells and given peri-tumoral injections of...
<p>Six mice/group were immunized three times with P<sub>5+435</sub> long peptide alone, long peptide...
<p><b>Copyright information:</b></p><p>Taken from "Repeated BCG treatment of mouse bladder selective...
Rationale: Organ- or tissue-specific antigens produced by normal tissue or by cancer cells could be ...
Background The therapeutic armamentarium of bladder cancer has been recently enriched with the intro...
<div><p>Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent ...
Approximately 80% of patients with advanced bladder cancer do not respond to immune checkpoint inhib...